Total raised
$42.5M
Last: Undisclosed 2020-06
Stage
Series A
Founded
2008
Headcount
62
HQ
Ness Ziona
Sector
Health Tech & Life Sciences
About
Mapi Pharma is a clinical-stage pharmaceutical company developing proprietary pharmaceuticals, including lifecycle management products such as Depot long-acting injections, complex active pharmaceutical ingredients, and formulations.
The company’s lead product is Glatiramer Acetate Depot, a once-monthly injection for the treatment of patients with multiple sclerosis. Mapi is also engaged in the development of Pregabalin ER for the treatment of neuropathic pain and epilepsy, Paliperidone Palmitate and Buspirone ER for the treatment of schizophrenia, and other long-acting Depot injectable treatments.
Funding history · 3 rounds · $42.5M total
2020-06
Undisclosed
$20.0M
2018-11
Convertible Debt
$10.0M
2015-05
Series A
$10.0M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Mapi Pharma's primary focus in pharmaceutical development?
- Mapi Pharma is a clinical-stage pharmaceutical company that develops proprietary pharmaceuticals, including lifecycle management products such as Depot long-acting injections, complex active pharmaceutical ingredients, and formulations.
- What is Mapi Pharma's lead product and its intended use?
- Mapi Pharma's lead product is Glatiramer Acetate Depot, a once-monthly injection designed for the treatment of patients with multiple sclerosis.
- When did Mapi Pharma receive its Series A funding, and who was one of the investors?
- In May 2015, Mapi Pharma received a $10 million Series A funding round, with Shavit Capital Fund as an investor.
- Which company invested in Mapi Pharma in June 2020?
- In June 2020, Mylan invested $20 million in Mapi Pharma through an undisclosed funding round.
- When did Mapi Pharma announce positive top-line results for its GA Depot Phase III trial?
- In September 2022, Mapi Pharma announced positive top-line results from its GA Depot Phase III trial for Relapsing forms of Multiple Sclerosis (RMS).
- What patent did Mapi Pharma receive in March 2022?
- In March 2022, Mapi Pharma received a U.S. patent covering methods of suppressing or alleviating primary or secondary progressive multiple sclerosis with a sustained-release Glatiramer Acetate Depot.
- Which company did Mapi Pharma sign an agreement with in October 2021 for distribution in the UAE?
- In October 2021, Mapi Pharma signed an agreement with Gaelan Medical Trade LLC to exclusively market and distribute Mapi products in the UAE.
- When did Mapi Pharma announce the first patient enrollment in the Phase III clinical trial of GA Depot for Relapsing Multiple Sclerosis (RMS)?
- In October 2019, Mapi Pharma announced the first patient enrollment in the Phase III clinical trial of GA Depot for Relapsing Multiple Sclerosis (RMS).
- What was a significant operational development for Mapi Pharma in April 2018?
- In April 2018, Mapi Pharma officially withdrew its $50 million US IPO.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
pain-reliefpharmaceuticalsdiabetesgeneric-drugsepilepsyschizophreniainflammatory-diseasespharma-companies